Diversified Trust Co trimmed its position in Roche Holdings AG Basel ADR (OTCMKTS:RHHBY) by 0.8% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 48,365 shares of the company’s stock after selling 399 shares during the period. Diversified Trust Co’s holdings in Roche Holdings AG Basel were worth $1,761,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Lenox Wealth Advisors LLC boosted its holdings in Roche Holdings AG Basel by 227.6% in the third quarter. Lenox Wealth Advisors LLC now owns 1,127 shares of the company’s stock worth $41,000 after acquiring an additional 783 shares in the last quarter. Dougherty Wealth Advisers LLC bought a new stake in Roche Holdings AG Basel in the second quarter worth $45,000. Motco bought a new stake in Roche Holdings AG Basel in the second quarter worth $47,000. MAI Capital Management boosted its holdings in Roche Holdings AG Basel by 27.6% in the second quarter. MAI Capital Management now owns 8,171 shares of the company’s stock worth $287,000 after acquiring an additional 1,768 shares in the last quarter. Finally, Boston Private Wealth LLC boosted its holdings in Roche Holdings AG Basel by 46.6% in the second quarter. Boston Private Wealth LLC now owns 10,240 shares of the company’s stock worth $361,000 after acquiring an additional 3,254 shares in the last quarter. 0.31% of the stock is currently owned by institutional investors.

A number of research analysts have recently issued reports on the company. Deutsche Bank raised Roche Holdings AG Basel from a “hold” rating to a “buy” rating in a report on Thursday, June 20th. UBS Group raised Roche Holdings AG Basel from a “neutral” rating to a “buy” rating in a report on Friday, July 26th. Zacks Investment Research raised Roche Holdings AG Basel from a “hold” rating to a “buy” rating and set a $37.00 price target on the stock in a report on Tuesday, July 9th. Liberum Capital downgraded Roche Holdings AG Basel from a “buy” rating to a “hold” rating in a report on Thursday, June 20th. Finally, ValuEngine downgraded Roche Holdings AG Basel from a “hold” rating to a “sell” rating in a report on Tuesday, September 10th. One analyst has rated the stock with a sell rating, four have given a hold rating and six have assigned a buy rating to the company’s stock. Roche Holdings AG Basel presently has a consensus rating of “Hold” and a consensus target price of $37.00.

Roche Holdings AG Basel stock traded down $0.03 during mid-day trading on Wednesday, reaching $35.94. 72,828 shares of the stock traded hands, compared to its average volume of 1,237,107. The stock has a market capitalization of $246.13 billion, a PE ratio of 15.49, a price-to-earnings-growth ratio of 2.31 and a beta of 0.49. Roche Holdings AG Basel ADR has a 12-month low of $28.74 and a 12-month high of $36.56. The business’s 50-day moving average is $35.10 and its 200-day moving average is $34.17.

Roche Holdings AG Basel Company Profile

Roche Holding AG engages in the diagnostics and prescription pharmaceuticals businesses in Switzerland, Germany, and internationally. It offers pharmaceutical products for treating anaemia, anticoagulation therapy, bone, cardiovascular, central nervous system, chlamydia, coagulation, dermatology, diabetes, gonorrhea, gout, hemostasis disorders, hepatitis B and C, HIV/AIDS, HPV, inflammatory and autoimmune, intensive care medicine, kidney and urogenital tract, leukemia, lipid and liver disorders, lymphoma, metabolic disorders, obesity, occult blood testing, ophthalmology, osteoporosis, pancreatitis, respiratory disorders, rheumatoid arthritis, sepsis, sexually transmitted infections, skin cancer, transplantation, tuberculosis, urinary tract infections, and West Nile virus and infectious diseases.

See Also: Buy-Side Analysts

Institutional Ownership by Quarter for Roche Holdings AG Basel (OTCMKTS:RHHBY)

Receive News & Ratings for Roche Holdings AG Basel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche Holdings AG Basel and related companies with MarketBeat.com's FREE daily email newsletter.